Biotech News

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma (NAMS)NewAmsterdam Pharma2026-05-01 20:57 ESTCompany update

NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with

Open original release

Related news

NAMSNewAmsterdam Pharma2026-07-24 12:00 EST

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

NAMSNewAmsterdam Pharma2026-07-01 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

NAMSNewAmsterdam Pharma2026-06-03 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions

NAMSNewAmsterdam Pharma2026-05-28 12:00 EST

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

NAMSNewAmsterdam Pharma2026-05-11 12:41 EST

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

NAMSNewAmsterdam Pharma2026-05-07 11:00 EST

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NAMSNewAmsterdam Pharma2026-04-08 12:00 EST

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

NAMSNewAmsterdam Pharma2026-03-23 12:00 EST

NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session

NAMSNewAmsterdam Pharma2026-02-25 13:00 EST

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

NAMSNewAmsterdam Pharma2026-02-18 12:01 EST

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

View all latest news

NewAmsterdam Pharma

NewAmsterdam Pharma is a cardiovascular-focused company developing therapies aimed at improving lipid management. Its story is centered on whether it can carve out a meaningful position in heart-health medicine.

Recent company news

NAMSBruker2026-07-24 20:01 EST

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

NAMSNewAmsterdam Pharma2026-07-24 12:00 EST

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

NAMSQuest Diagnostics2026-07-23 10:45 EST

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

NAMSMolina Healthcare2026-07-22 20:15 EST

Molina Healthcare Reports Second Quarter 2026 Financial Results

NAMSAxon Enterprise, Inc.2026-07-22 20:01 EST

Axon to Release Second Quarter 2026 Earnings on August 5, 2026

Stock data

Close: 30.55 USD
Market cap: 3.71B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States